PMID- 35965822
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220816
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 10
IP  - 14
DP  - 2022 Jul
TI  - Effects of 4-DAMP on allergic rhinitis in guinea pigs and its potential 
      mechanism.
PG  - 774
LID - 10.21037/atm-22-2998 [doi]
LID - 774
AB  - BACKGROUND: Allergic rhinitis (AR) is a non-infectious chronic inflammatory 
      disease of the nasal mucosa mainly mediated by immunoglobulin E (IgE), which 
      seriously affects the life quality of affected patients. This study aimed to 
      observe the effects of 1,1-dimethyl-4-diphenylacetoxypiperidinium iodide (4-DAMP; 
      a selective M3 receptor antagonist) on ovalbumin (OVA)-induced AR guinea pigs, 
      and to explore its potential mechanism of involvement. METHODS: An AR model was 
      established by inducing male guinea pigs (4-6 weeks of age) with OVA. AR guinea 
      pigs were randomly divided into a model group, 0.6 mg/kg ipratropium bromide (IB) 
      group, 0.12 and 0.6 mg/kg 4-DAMP group (n=18). The 0.6 mg/kg IB group, 0.12 and 
      0.6 mg/kg 4-DAMP group animals were treated with IB (0.6 mg/kg) and 4-DAMP (0.12 
      or 0.6 mg/kg) by intranasal instillation per nostril daily. Animals in the model 
      group and normal group were treated with saline as control. The AR symptom scores 
      were counted and nasal secretion weights were measured. Histopathological methods 
      were used to observe nasal mucosa. Enzyme-linked immunosorbent assay (ELISA) was 
      used to detect the levels of histamine and cytokines. Western blot and 
      quantitative real-time polymerase chain reaction (qRT-PCR) were used to detect 
      the expressions of mucin 5AC (MUC5AC), matrix metalloproteinase 9 (MMP9), and 
      epidermal growth factor receptor (EGFR). RESULTS: Compared with model group 
      animals, the AR symptom scores and nasal secretion weights of animals treated 
      with 4-DAMP were reduced significantly, goblet cell metaplasia was reversed, and 
      eosinophil infiltration was visibly alleviated. The levels of histamine and 
      cytokines in nasal lavage fluid (NLF) were decreased, and the protein and 
      messenger RNA (mRNA) expressions of MUC5AC, MMP9, and EGFR were inhibited. 
      CONCLUSIONS: Treatment with 4-DAMP has a certain effect on AR, especially for 
      mucus hypersecretion, which provides a new idea for clinical treatment of AR.
CI  - 2022 Annals of Translational Medicine. All rights reserved.
FAU - Huang, Yu
AU  - Huang Y
AD  - Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Long, Rui
AU  - Long R
AD  - Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Tang, Yiding
AU  - Tang Y
AD  - Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Li, Juan
AU  - Li J
AD  - Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Meng, Long
AU  - Meng L
AD  - Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Yang, Jiadan
AU  - Yang J
AD  - Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Qiu, Feng
AU  - Qiu F
AD  - Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC9372692
OTO - NOTNLM
OT  - 1,1-dimethyl-4-diphenylacetoxypiperidinium iodide (4-DAMP)
OT  - M3 receptor
OT  - allergic rhinitis (AR)
OT  - chronic inflammatory
OT  - hypersecretion
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://atm.amegroups.com/article/view/10.21037/atm-22-2998/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2022/08/16 06:00
MHDA- 2022/08/16 06:01
PMCR- 2022/07/01
CRDT- 2022/08/15 03:29
PHST- 2022/05/19 00:00 [received]
PHST- 2022/06/30 00:00 [accepted]
PHST- 2022/08/15 03:29 [entrez]
PHST- 2022/08/16 06:00 [pubmed]
PHST- 2022/08/16 06:01 [medline]
PHST- 2022/07/01 00:00 [pmc-release]
AID - atm-10-14-774 [pii]
AID - 10.21037/atm-22-2998 [doi]
PST - ppublish
SO  - Ann Transl Med. 2022 Jul;10(14):774. doi: 10.21037/atm-22-2998.